Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies: Focus on Cardiovascular and Pancreatic Side Effects

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Drug Safety

• Publication date

  2014-11-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40264-014-0238-8PMID 25391858
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas

  2015cited by this paper
• Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials.

  2014cited by this paper
• GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

  2014cited by this paper
• Risk of pancreatitis in patients treated with incretin-based therapies

  2014cited by this paper
• High fat diet and GLP-1 drugs induce pancreatic injury in mice.

  2014cited by this paper
• Hope and fear for new classes of type 2 diabetes drugs: is there preclinical evidence that incretin-based therapies alter pancreatic morphology?

  2014cited by this paper
• LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes

  2014cited by this paper
• Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies

  2014cited by this paper
• Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect?

  2014cited by this paper
• Pancreatic safety of incretin-based drugs--FDA and EMA assessment.

  2014cited by this paper
• Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin

  2014cited by this paper
• Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.

  2014cited by this paper
• Dipeptidyl peptidase‐4 inhibitors and pancreatitis risk: a meta‐analysis of randomized clinical trials

  2014cited by this paper
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?

  2013cited by this paper
• A Critical Analysis of the Clinical Use of Incretin-Based Therapies

  2013cited by this paper
• Diabetes and pancreatic cancer.

  2013cited by this paper
• A Critical Analysis of the Clinical Use of Incretin-Based Therapies

  2013cited by this paper
• Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

  2013influential reference
• The cardiovascular safety of incretin-based therapies: a review of the evidence

  2013cited by this paper
• Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

  2013cited by this paper
• Extra‐pancreatic effects of incretin‐based therapies: potential benefit for cardiovascular‐risk management in type 2 diabetes

  2013cited by this paper
• Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors

  2013cited by this paper
• Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat‐rich meal in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, cross‐over trial

  2013cited by this paper
• Glycaemic efficacy of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors as add‐on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis

  2012cited by this paper
• DPP4 inhibitor vildagliptin preserves b -cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice

  2012cited by this paper
• Tu1502 Longitudinal Monitoring of Lipase and Amylase in Adults With Type 2 Diabetes and Obesity: Evidence From Two Phase 3 Randomized Clinical Trials With the Once-Daily GLP-1 Analog Liraglutide

  2012cited by this paper
• Effectiveness of interventions for reducing diabetes and cardiovascular disease risk in people with metabolic syndrome: systematic review and mixed treatment comparison meta‐analysis

  2012cited by this paper
• No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks

  2012cited by this paper
• Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies

  2012cited by this paper
• The Human GLP-1 Analog Liraglutide and the Pancreas

  2012cited by this paper
• Acute pancreatitis due to diabetes: the role of hyperglycaemia and insulin resistance.

  2012cited by this paper
• Diabetes and pancreatic cancer.

  2012cited by this paper
• Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.

  2012cited by this paper
• DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis

  2011cited by this paper
• Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs

  2011cited by this paper
• The safety of incretin-based therapies--review of the scientific evidence.

  2011cited by this paper
• Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review

  2011cited by this paper
• The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes

  2011cited by this paper
• Evidence Linking Hypoglycemic Events to an Increased Risk of Acute Cardiovascular Events in Patients With Type 2 Diabetes

  2011cited by this paper
• A cohort study of acute pancreatitis in relation to exenatide use

  2011cited by this paper
• Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.

  2011cited by this paper
• Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.

  2010cited by this paper
• GLP-1–Based Therapy for Diabetes: What You Do Not Know Can Hurt You

  2010cited by this paper
• Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

  2010cited by this paper
• Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents.

  2010cited by this paper
• Glucagon-like peptide 1--a cardiologic dimension.

  2010cited by this paper
• Effects of Intensive Glucose Lowering in Type 2 Diabetes

  2009cited by this paper
• The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart.

  2009cited by this paper
• A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.

  2009cited by this paper
• GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

  2009cited by this paper
• Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials

  2009cited by this paper
• Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

  2009cited by this paper
• Beneficial Endocrine but adverse Exocrine effects of Sitagliptin in the HIP rat model of Type 2 Diabetes, interactions with Metformin.

  2009cited by this paper
• Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.

  2009cited by this paper
• Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes

  2009cited by this paper
• Glucagon-Like Peptide-1 Receptor Activation Modulates Pancreatitis-Associated Gene Expression But Does Not Modify the Susceptibility to Experimental Pancreatitis in Mice

  2009cited by this paper
• Glucose control and vascular complications in veterans with type 2 diabetes.

  2009cited by this paper
• Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides.

  2009cited by this paper
• Pancreatic duct replication is increased with obesity and type 2 diabetes in humans

  2009cited by this paper
• Effect of a multifactorial intervention on mortality in type 2 diabetes.

  2008cited by this paper
• Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

  2008cited by this paper
• Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat

  2008cited by this paper
• The Role of Incretins in Glucose Homeostasis and Diabetes Treatment

  2008cited by this paper
• Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes

  2008cited by this paper
• Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

  2008cited by this paper
• GLP‐1: physiological effects and potential therapeutic applications

  2008cited by this paper
• Glucagon-like peptide-1, glucose homeostasis and diabetes.

  2008cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Exenatide (exendin-4)-induced pancreatitis: a case report.

  2006cited by this paper
• The biology of incretin hormones.

  2006cited by this paper
• Activation of Glucagon-Like Peptide-1 Receptor Signaling Does Not Modify the Growth or Apoptosis of Human Pancreatic Cancer Cells

  2006cited by this paper
• Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes

  2006cited by this paper
• Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes.

  2006cited by this paper
• Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.

  2006cited by this paper
• Trends in complexity of diabetes care in the United States from 1991 to 2000.

  2004cited by this paper
• Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.

  2003cited by this paper
• Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.

  2003cited by this paper
• β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes

  2003cited by this paper
• Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

  2002cited by this paper
• Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

  2002cited by this paper
• Metabolic Syndrome: Pathophysiology and Implications for Management of Cardiovascular Disease

  2002cited by this paper
• Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats.

  2000cited by this paper
• Glucagon-Like Peptide-1 Induces Cell Proliferation and Pancreatic-Duodenum Homeobox-1 Expression and Increases Endocrine Cell Mass in the Pancreas of Old, Glucose-Intolerant Rats.

  2000cited by this paper
• Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells.

  1999cited by this paper
• Science, medicine, and the future

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Science, medicine, and the future Non-insulin dependent diabetes mellitus: the gathering storm

  1997cited by this paper
• O R I G I N a L I N V E S T I G a T I O N Open Access

  year unknowncited by this paper

• Generation and characterisation of C-terminally stabilised PYY molecules with potential in vivo NPYR2 activity.

  2020cites this paper
• Clinical pharmacology of glucagon-like peptide-1 receptor agonists

  2018cites this paper
• Chapter 3 – Glucagon-Like Peptide 1 and Human Obesity

  2018cites this paper
• No change in serum incretins levels but rise of leptin levels after smoking cessation: a pilot study.

  2016cites this paper
• Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity

  2016cites this paper
• Urinary metabolomic profiling in mice with diet-induced obesity and type 2 diabetes mellitus after treatment with metformin, vildagliptin and their combination.

  2016cites this paper
• Leaf Extract from Lithocarpus polystachyus Rehd. Promote Glycogen Synthesis in T2DM Mice

  2016cites this paper
• Lixisenatida en pacientes con diabetes tipo 2 y obesidad: más allá del control glucémico

  2016cites this paper
• Lixisenatide clinical experience on patients with type 2 diabetes and obesity in endocrinology offices in Malaga.

  2015cites this paper
• Experiencia clínica con lixisenatida en pacientes con diabetes tipo 2 y obesidad en consultas de atención especializada en Málaga

  2015cites this paper